February 3, 2017
FDA approves Bristol-Myers’s Opdivo for urothelial bladder cancer
U.S. Food and Drug Administration (FDA) has approved Bristol-Myers’s Opdivo injection, for treatment of urothelial carcinoma (mUC).
Pharmaceuticals, Biotechnology and Life Sciences
Category: Approval
February 2, 2017
Eli Lilly keeps Alimta patent in Japan for now, new challenges on the way
Japan IP High Court confirmed validity of Eli Lilly’s Alimta vitamin regimen patents, and has invalidated trials initiated by Sawai regarding Lilly’s vitamin regimen patents for Alimta.
February 2, 2017
MENA biologics industry first ever Biopharma Conference at CPhI Istanbul 2017
With the goal of developing Turkey as an R&D and technology hub, the Government has put place a number of measures to stimulate expansion of biotechnology and biopharmaceutical activities.
February 2, 2017
Pharmapack Europe 2017 Award Winners: Vial injector, pharma compliance pack, smart packaging and autoinjector for prefilled syringes named best innovations
UBM EMEA’s Pharmapack Europe 2017 has named the winners of the 2017 Pharmapack Awards on Wednesday, picking four innovations in the Exhibitor Innovation category, while two winners were chosen to get awards in the Health Product category.
February 2, 2017
Simens Healthcare palces first order from BioPorto
Danish provider of clinical diagnostic tests BioPorto, has finalized a distribution deal with Simens Healthcare for delivery of a NGAL test adapted for Siemens Healthcare BN II and BN ProSpec Systems.
February 2, 2017
AstraZeneca’s sales drop, expects to launch several new drugs this year
AstraZeneca’s hopes to launch several cancer, respiratory and metabolic diseases drugs, as it expects to see the effects of its long-term growth. The drugmaker nears the end of its patent-expiry period as it expects to bring new medicines to the stores is.
February 1, 2017
Pfizers full years earnings up 4%, Q1 2017 dividend rise 7%
Pfizer has reported 11% growth for full-year 2016 revenues, reaching $52.8 billion, including the business from Hospira and the legacy of Medivation. Net income for full year was $7,215 million which is up 4% from last years total net income of $6,960.
February 1, 2017
Allergan completes $2.9 LifeCell buy, boosts up its plastic surgery business
Allergan has completed the $2.9 billion purchase of Acelity’s subsidiary LifeCell, adding commercial products to its regenerative medicine portfolio, and LifeCell’s innovative manufacturing capabilities and its R&D operations, based in New Jersey.
February 1, 2017
Medivir studies potentially $6 billion annually worth drug
Data Monitoring Committee (DMC) held its fourth and final scheduled meeting and recommended continuation of the ongoing randomized, double-blind phase IIa study of Medivir’s MIV-711 in patients with moderate knee osteoarthritis.
February 1, 2017
Biomarin’s hemophilia drug nets PRIME status in Europe
BioMarin Pharmaceutical’s treatment for hemophilia has been accepted for PRIME (Priority Medicines) scheme from the European Medicines Agency (EMA).